FDA Meeting on COVID Vaccine for Children
2021-10-26T20:25:49-04:00https://ximage.c-spanvideo.org/eyJidWNrZXQiOiJwaWN0dXJlcy5jLXNwYW52aWRlby5vcmciLCJrZXkiOiJGaWxlc1wvOWVkXC8yMDIxMTAyNjA4MzYzMjAwM19oZC5qcGciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY292ZXIiLCJoZWlnaHQiOjUwNn19fQ==The Food and Drug Administration Advisory Committee met to discuss emergency use authorization for Pfizer’s COVID-19 vaccine in children ages 5 to 11 years old. FDA and Centers for Disease Control and Prevention officials presented various data and topics, including the epidemiology of COVID-19 among children in this age group, post-COVID-19 symptoms, and vaccine dosage compared to older children. Pfizer officials presented clinical data on the safety and efficacy of the vaccine while FDA officials talked about their review of the submission. During the public meeting portion, the committee heard comments from the public, followed by an open discussion and vote on emergency use authorization.
The Food and Drug Administration Advisory Committee met to discuss emergency use authorization for Pfizer’s COVID-19 vaccine in children age… read more
The Food and Drug Administration Advisory Committee met to discuss emergency use authorization for Pfizer’s COVID-19 vaccine in children ages 5 to 11 years old. FDA and Centers for Disease Control and Prevention officials presented various data and topics, including the epidemiology of COVID-19 among children in this age group, post-COVID-19 symptoms, and vaccine dosage compared to older children. Pfizer officials presented clinical data on the safety and efficacy of the vaccine while FDA officials talked about their review of the submission. During the public meeting portion, the committee heard comments from the public, followed by an open discussion and vote on emergency use authorization. close
Points of Interest
For quick viewing, C-SPAN provides Points of Interest markers for some events.
Click the play button and tap the screen to see the at the bottom of the player. Tap the to see a complete list of all Points of Interest - click on any moment in the list and the video will play.
Points of Interest
For quick viewing, C-SPAN provides Points of Interest markers for some events.
Click the play button and move your cursor over the video to see the . Click on the marker to see the description and watch.
You can also click the in the lower left of the video player to see a complete list of all Points of Interest from this program - click on any moment in the list and the video will play.
People in this video
- Prabhakara Atreya Director U.S. Food and Drug Administration->Scientific Advisers and Consultants
- Richard Forshee Associate Director U.S. Food and Drug Administration->Research
- Peter W. Marks M.D. Director U.S. Food and Drug Administration->Center for Biologics Evaluation and Research
- Leslie Ball M.D. Medical Officer U.S. Food and Drug Administration->Vaccines and Related Product Applications
-
-
Doran Fink Deputy Director U.S. Food and Drug Administration->Vaccines and Related Biological Products Advisory Committee
-
-
- William Gruber M.D. Senior Vice President Pfizer, Inc.->Vaccine Clinical Research and Development
- Fiona Havers M.D. Medical Officer Centers for Disease Control and Prevention->National Center for Immunization and Respiratory Diseases
-
-
-
-
-
-
-
- Ramachandra Naik Chair U.S. Food and Drug Administration->Vaccines and Related Products Applications Committee
- Michael Nelson M.D. Professor University of Virginia->Medical School
-
- Matthew Oster M.D. Associate Professor Emory University->School of Medicine
-
-
-
-
-
-
- Hong Yang Senior Adviser U.S. Food and Drug Administration->Benefit-Risk Assessment Office
Hosting Organization
Related Video
-
Dr. Paul Offit on Boosters and Vaccines for Children
Dr. Paul Offit talked about booster shots and the approval of COVID-19 vaccines for children.
-
Dr. Paul Offit on COVID-19 Vaccines for Children
FDA Advisory Committee member Dr. Paul Offit talked about the approval of COVID-19 vaccines for children.
-
FDA Open Meeting on Johnson & Johnson COVID-19 Vaccine, Part 1
The Food and Drug Administration (FDA) held a virtual open meeting to discuss emergency use authorization for the Johnso…
-
FDA Open Meeting on Johnson & Johnson COVID-19 Vaccine, Part 2
The Food and Drug Administration (FDA) held a virtual open meeting to discuss emergency use authorization for the Johnso…
User Created Clips from This Video
-
- 9 minutes
- 165 views
-
- 4 minutes
- 148 views
-
- 2 minutes
- 110 views
-
- 2 minutes
- 86 views